 |
PDBsum entry 1vpp
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Growth factor/growth factor inhibitor
|
PDB id
|
|
|
|
1vpp
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
96 a.a.
|
 |
|
|
|
|
|
|
|
90 a.a.
|
 |
|
|
|
|
|
|
|
20 a.a.
|
 |
|
|
|
|
|
|
|
18 a.a.
|
 |
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Crystal structure of the complex between vegf and a receptor-Blocking peptide.
|
 |
|
Authors
|
 |
C.Wiesmann,
H.W.Christinger,
A.G.Cochran,
B.C.Cunningham,
W.J.Fairbrother,
C.J.Keenan,
G.Meng,
A.M.De vos.
|
 |
|
Ref.
|
 |
Biochemistry, 1998,
37,
17765-17772.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
Vascular endothelial growth factor (VEGF) is a specific and potent angiogenic
factor and, therefore, a prime therapeutic target for the development of
antagonists for the treatment of cancer. As a first step toward this goal, phage
display was used to generate peptides that bind to the receptor-binding domain
(residues 8-109) of VEGF and compete with receptor [Fairbrother, W. J.,
Christinger, H. W., Cochran, A. G., Fuh, G., Keenan, C. J., Quan, C., Shriver,
S. K., Tom, J. Y. K., Wells, J. A., and Cunningham, B. C. (1999) Biochemistry
38, 17754-17764]. The crystal structure of VEGF in complex with one of these
peptides was solved and refined to a resolution of 1.9 A. The 20-mer peptide is
unstructured in solution and adopts a largely extended conformation when bound
to VEGF. Residues 3-8 form a beta-strand which pairs with strand beta6 of VEGF
via six hydrogen bonds. The C-terminal four residues of the peptide point away
from the growth factor, consistent with NMR data indicating that these residues
are flexible in the complex in solution. In contrast, shortening the N-terminus
of the peptide leads to decreased binding affinities. Truncation studies show
that the peptide can be reduced to 14 residues with only moderate effect on
binding affinity. However, because of the extended conformation and the scarcity
of specific side-chain interactions with VEGF, the peptide is not a promising
lead for small-molecule development. The interface between the peptide and VEGF
contains a subset of the residues recognized by a neutralizing Fab fragment and
overlaps partially with the binding site for the Flt-1 receptor. The location of
the peptide-binding site and the hydrophilic character of the interactions with
VEGF resemble more the binding mode of the Fab fragment than that of the
receptor.
|
 |
|
|
|
|
 |